High-Dose Epidermal Radionuclide Therapy with (188) Re (Rhenium) Resin in a Patient with Multiple Actinic Keratoses

对多发性日光性角化病患者进行高剂量表皮放射性核素治疗(使用 188Re(铼)树脂)。

阅读:1

Abstract

Aim  High-dose epidermal radionuclide therapy using a nonsealed (188) Re (Rhenium) resin is an alternative treatment option for nonmelanoma skin cancer. In this case study, we present the possible use of this therapy in a patient with multiple actinic keratosis (AK), which is a precancer of the skin. Methods  A 55-year-old male was presented in our department with multiple AK, located on the cheek, temporal, and frontal area, with 1, 1, 2.1, and 2.5 cm (2) surface. Applied activity was 80, 80, 167, and 168 MBq (188) Re with a target absorbed dose for each lesion 35 Gy at 1 mm. The treatment was well tolerated. Results  At 17 months' follow-up, all treated area showed complete remission. There were no side effects, except mild focal hypopigmentation. Conclusion  This case demonstrates the high potential of epidermal radionuclide therapy with a nonsealed (188) Re as a noninvasive, effective, and well-tolerated therapy option for patients with multiple AK, when surgery is difficult to perform or not recommended of other reasons.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。